ClinicalTrials.gg
CompletedNCT05027269MARINAUpdated Sep 28, 2026Results posted

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

A Phase 1/2 interventional study of AOC 1001 and Placebo in DM1, Myotonic Dystrophy 1 and Myotonic Dystrophy, sponsored by Avidity Biosciences, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Avidity Biosciences, Inc. (part of Novartis) · Phase 1/2, Interventional, and Treatment

Updated Sep 28, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.

Enrollment
14th of 22
39 · median 46
Started
2021
with 3 others
Phase 1/2
7 of 43
2 open now
Registered
20th of 43
by date
Lead sponsor
4 of 43
Avidity Biosciences, Inc.

Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 1/2, and was the 20th registered.

Myotonic Dystrophy

126 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Myotonic Dystrophy with a site in United States, or all of them as a file.
02

Study summary

AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients (MARINA).

Part A is a single dose design with 1 cohort (dose level). In Part A, the patient duration is 6 months as the treatment period is 1 day followed by a 6 month follow-up period.

Part B is a multiple-ascending dose design with 2 cohorts (dose levels). In Part B, the patient duration is 6 months as the treatment period is 3 months followed by a 3 month follow-up period.

03

Conditions studied

  • DM1
  • Myotonic Dystrophy 1
  • Myotonic Dystrophy
  • Myotonic Dystrophy Type 1 (DM1)
  • Dystrophy Myotonic
  • Myotonic Disorders
  • Steinert Disease
  • Myotonic Muscular Dystrophy

Browse trials for

Keywords

  • DM1
  • Myotonic Dystrophy 1
  • Myotonic Dystrophy Type 1 (DM1)
  • Myotonic Dystrophy
  • DM
  • Dystrophy Myotonic
  • Myotonic Disorders
  • Steinert Disease
  • MARINA
  • Avidity Biosciences
  • Avidity
  • AOC 1001
  • Myotonic Muscular Dystrophy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Genetic diagnosis of DM1 (CTG repeat length ≥ 100)
  • Clinician assessed signs of DM1
  • Ability to walk independently (orthoses and ankle braces allowed) for at least 10 meters at screening

Key Exclusion Criteria:

  • Diabetes that is not adequately controlled
  • > 35 kg/m2
  • Uncontrolled hypertension
  • Congenital DM1
  • History of tibialis anterior (TA) within 3 months of Day 1 or planning to undergo TA biopsies during study period
  • Recently treated with an drug
  • Treatment with anti-myotonic medication within 14 days of Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Part A Single Dose: AOC 1001 Dose Level 1

    AOC 1001 will be administered once.

    Drug: AOC 1001

  • Placebo comparator
    Part A Single Dose: Placebo

    Saline will be administered once.

    Drug: Placebo

  • Experimental
    Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2 & 3

    AOC 1001 will be administered three times.

    Drug: AOC 1001

  • Placebo comparator
    Part B Multiple Ascending Dose: Placebo

    Saline will be administered three times.

    Drug: Placebo

Interventions

  • AOC 1001 will be administered by intravenous (IV) infusion.

  • DrugPlacebo

    Placebo will be administered by intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Frequency of Treatment Emergent Adverse Events (TEAEs)

    Cumulative number of participants with treatment emergent adverse events at the end of study.

    Time frame: Through study completion, up to Day 183

Secondary outcomes

  1. Plasma PK Parameters

    Maximum concentration in Plasma (Cmax)

    Time frame: Day 1

  2. Plasma Pharmacokinetic (PK) Parameters

    Time to maximum plasma concentration (Tmax)

    Time frame: Day 1

  3. Plasma Pharmacokinetic (PK) Parameters

    Terminal Half-life (t1/2)

    Time frame: Day 1

  4. Plasma Pharmacokinetic (PK) Parameters

    Area Under the Concentration-time Curve (AUC) obtained until the last observed timepoint

    Time frame: Day 1

  5. Urine Pharmacokinetic (PK) Parameters

    fraction excreted (fe) in urine in first 24 hours

    Time frame: Day 1

  6. Change From Baseline in DMPK mRNA Knockdown

    percent change from baseline in DMPK mRNA level

    Time frame: Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)

  7. Absolute Change From Baseline in 4 Gene Spliceopathy

    Change from baseline in 4 gene panel mean scaled percent spliced in value. The 4 gene panel includes the following genes: CLCN1, CACNA1S, ATP2A1, and BIN1

    Time frame: Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)

  8. AOC 1001 Concentration Levels in Plasma, Urine, and Muscle Tissue

    AOC 1001 concentration measures in plasma, urine, and muscle tissue. Assessments below lower limit of quantification are set to zero.

    Time frame: Up to Day 43

07

Results

Posted Sep 28, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001Part B Multiple Dose: Pooled Placebo
Started629148
Completed629128
Not completed00020
Withdrew: Lost to follow-up00010
Withdrew: Participant was randomized but not dosed00010

Outcome measures

PrimaryFrequency of Treatment Emergent Adverse Events (TEAEs)

Cumulative number of participants with treatment emergent adverse events at the end of study.

Time frame:
Through study completion, up to Day 183
Reported as:
Count of participants · Participants
Frequency of Treatment Emergent Adverse Events (TEAEs)
ParticipantsPart A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001Part B Multiple Dose: Pooled Placebo
Frequency of Treatment Emergent Adverse Events (TEAEs)619137
SecondaryPlasma PK Parameters

Maximum concentration in Plasma (Cmax)

Time frame:
Day 1
Reported as:
Mean · ng/mL
Plasma PK Parameters
ng/mLPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Plasma PK Parameters23600 ± 361050400 ± 9380101000 ± 19200
SecondaryPlasma Pharmacokinetic (PK) Parameters

Time to maximum plasma concentration (Tmax)

Time frame:
Day 1
Reported as:
Geometric mean · hours
Plasma Pharmacokinetic (PK) Parameters
hoursPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Plasma Pharmacokinetic (PK) Parameters0.542 (0.47 to 0.60)1.707 (0.72 to 4.77)2.204 (1.07 to 7.73)
SecondaryPlasma Pharmacokinetic (PK) Parameters

Terminal Half-life (t1/2)

Time frame:
Day 1
Reported as:
Mean · hours
Plasma Pharmacokinetic (PK) Parameters
hoursPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Plasma Pharmacokinetic (PK) Parameters28.42 ± 2.8240.61 ± 9.6949.60 ± 6.08
SecondaryPlasma Pharmacokinetic (PK) Parameters

Area Under the Concentration-time Curve (AUC) obtained until the last observed timepoint

Time frame:
Day 1
Reported as:
Mean · h*ng/mL
Plasma Pharmacokinetic (PK) Parameters
h*ng/mLPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Plasma Pharmacokinetic (PK) Parameters850000 ± 1370002470000 ± 6290005490000 ± 1570000
SecondaryUrine Pharmacokinetic (PK) Parameters

fraction excreted (fe) in urine in first 24 hours

Time frame:
Day 1
Reported as:
Mean · percent of total siRNA component
Urine Pharmacokinetic (PK) Parameters
percent of total siRNA componentPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Urine Pharmacokinetic (PK) Parameters3.724 ± 0.7474.216 ± 2.0844.308 ± 2.087
SecondaryChange From Baseline in DMPK mRNA Knockdown

percent change from baseline in DMPK mRNA level

Time frame:
Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
Reported as:
Mean · % change
Change From Baseline in DMPK mRNA Knockdown
% changePart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Pooled Placebo
Change From Baseline in DMPK mRNA Knockdown-46.36 ± 8.85-44.39 ± 3.80-36.81 ± 6.341.46 ± 11.17
SecondaryAbsolute Change From Baseline in 4 Gene Spliceopathy

Change from baseline in 4 gene panel mean scaled percent spliced in value. The 4 gene panel includes the following genes: CLCN1, CACNA1S, ATP2A1, and BIN1

Time frame:
Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
Reported as:
Mean · percent
Absolute Change From Baseline in 4 Gene Spliceopathy
percentPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Pooled Placebo
Absolute Change From Baseline in 4 Gene Spliceopathy-3.13 ± 8.39-16.72 ± 7.65-15.81 ± 10.30-6.97 ± 9.68
SecondaryAOC 1001 Concentration Levels in Plasma, Urine, and Muscle Tissue

AOC 1001 concentration measures in plasma, urine, and muscle tissue. Assessments below lower limit of quantification are set to zero.

Time frame:
Up to Day 43
Reported as:
Mean · nM
AOC 1001 Concentration Levels in Plasma, Urine, and Muscle Tissue
nMPart A Single Dose: 1 mg/kg AOC 1001Part B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4 mg/kg AOC 1001
Plasma siDMPK.19: first dose, end of Infusion1749 ± 109.263670.18 ± 236.297234.72 ± 415.56
Plasma siDMPK.19: first dose, 1 hour post-infusion1623.12 ± 86.833632.49 ± 246.597281.03 ± 365.77
Plasma siDMPK.19: first dose, 2 hours post infusion1596.32 ± 89.483410.50 ± 276.987050.49 ± 379.32
Plasma siDMPK.19: first dose, 6 hours post infusion1379.38 ± 102.253018.71 ± 243.956419.49 ± 399.580
Plasma siDMPK.19: first dose, 24 hours post infusion841.88 ± 56.132052.98 ± 148.0974666.17 ± 301.02
Plasma siDMPK.19: first dose, 8 days post infusion38.18 ± 10.16152.66 ± 27.95465.92 ± 41.74
Plasma siDMPK.19: first dose, 15 days post infusion0.46 ± 0.189.46 ± 8.7944.01 ± 17.99
Plasma siDMPK.19: first dose, 29 days post infusion0.00 ± 0.000.11 ± 0.060.69 ± 0.14
Plasma siDMPK.19: first dose, 43 days post infusion0.00 ± 0.000.00 ± 0.000.05 ± 0.03
Urine siDMPK.19: first dose, 0-6 hours post infusion55.38 ± 26.22256.64 ± 73.72196.331 ± 38.415
Urine siDMPK.19: first dose, 6-12 hours227.91 ± 53.89419.66 ± 82.97653.42 ± 100.98
Urine siDMPK.19: first dose, 12-24 hours161.79 ± 26.95387.46 ± 113.47648.11 ± 109.66
Muscle siDMPK.19: first dose, Day 43 (1 mg/kg) or 92 (2 mg/kg and 4 mg/kg)0.085 ± 0.0540.424 ± 0.1591.414 ± 0.417

Adverse events

Collected over Treatment-emergent adverse events (TEAES) were collected from the start of the first dose administration through study completion (approximately 6 months for participants who completed the study).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Single Dose: 1 mg/kg AOC 10010/6 (0%)0/6 (0%)6/6 (100%)
Part A Single Dose: Placebo0/2 (0%)0/2 (0%)1/2 (50%)
Part B Multiple Dose: 2 mg/kg ACO 10010/9 (0%)1/9 (11.1%)9/9 (100%)
Part B Multiple Dose: 4 mg/kg AOC 10010/13 (0%)1/13 (7.7%)13/13 (100%)
Part B Multiple Dose: Pooled Placebo0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventPart A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg ACO 1001Part B Multiple Dose: 4 mg/kg AOC 1001Part B Multiple Dose: Pooled Placebo
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/60/21/90/130/8
Thalmus haemorrhageNervous system disorders0/60/20/91/130/8
Most frequent other events
Showing 10 of 85
Most frequent other events
EventPart A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg ACO 1001Part B Multiple Dose: 4 mg/kg AOC 1001Part B Multiple Dose: Pooled Placebo
fallInjury, poisoning and procedural complications1/61/21/90/134/8
arthropod biteInjury, poisoning and procedural complications0/61/20/90/130/8
concussionInjury, poisoning and procedural complications1/61/20/90/130/8
nasopharyngitisInfections and infestations0/61/20/92/130/8
paraesthesiaNervous system disorders0/61/21/91/130/8
coughRespiratory, thoracic and mediastinal disorders0/61/20/90/130/8
anaemiaBlood and lymphatic system disorders0/60/21/96/130/8
procedural painInjury, poisoning and procedural complications0/60/24/94/130/8
COVID-19Infections and infestations2/60/23/92/131/8
arthralgiaMusculoskeletal and connective tissue disorders2/60/21/90/131/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Part B Multiple Dose: Pooled PlaceboTotal
<=18 years000000
Between 18 and 65 years62913838
>=65 years000000
Age, Continuous
Age, Continuous(years)Part A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Part B Multiple Dose: Pooled PlaceboTotal
Mean37.0 ± 1840.5 ± 9.237.6 ± 13.644.0 ± 12.448.0 ± 8.542.0 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Part A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Part B Multiple Dose: Pooled PlaceboTotal
Female5199428
Male1104410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Part B Multiple Dose: Pooled PlaceboTotal
American Indian or Alaska Native000000
Asian000101
Native Hawaiian or Other Pacific Islander000000
Black or African American000101
White62910835
More than one race000000
Unknown or Not Reported000101
Region of Enrollment
Region of Enrollment(participants)Part A Single Dose: 1 mg/kg AOC 1001Part A Single Dose: PlaceboPart B Multiple Dose: 2 mg/kg AOC 1001Part B Multiple Dose: 4mg/kg AOC 1001Part B Multiple Dose: Pooled PlaceboTotal
United States62913838
08

Study locations

8 sites
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66205, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Ohio State University
    Columbus, Ohio 43221, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
09

References and documents

Publications

  • Johnson NE, Tai LJ, Hamel JI, Day JW, Statland JM, Soltanzadeh P, Subramony SH, Thornton CA, Arnold WD, Wicklund M, Freimer ML, Eichinger K, Dekdebrun J, Chen CY, Goel V, McEvoy B, Zhu Y, Hughes SG, Ackermann EJ, Levin AA. An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1. N Engl J Med. 2026 Feb 19;394(8):763-772. doi: 10.1056/NEJMoa2407326. PubMed 41707138 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Feb 2023, 15 months.

Results were first posted in Sep 2026, 3 years 7 months after primary completion. A results delay was requested in Feb 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 30, 2021
StartActual
Oct 28, 2021
Primary completionActual
Feb 14, 2023
CompletionActual
Feb 14, 2023
Results delay requested
Feb 1, 2024
Results first posted
Sep 28, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedFrequency of treatment emergent adverse eventsTreatment Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to Day 183
Sep 28, 2026
Secondary outcomes
8 edited
What changed in the outcomes
  • EditedPlasma pharmacokinetic (PK) parametersPK ParametersTime frame: Through study completion, up to Day 183 → Day 1
  • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
  • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
  • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
  • EditedUrine pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
  • EditedAOC 1001 levelsConcentration Levels in muscle tissuePlasma, Urine, and Muscle TissueTime frame: Through study completion, up to Day 183 → Up to Day 43
  • EditedChange and percentage change from baselineFrom Baseline in DMPK mRNA knockdownKnockdownTime frame: Through study completion, up to Day 183 → Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
  • EditedAbsolute Change and percentage change from baselineFrom Baseline in 4 Gene SpliceopathyTime frame: Through study completion, up to Day 183 → Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedFrequency of treatment emergent adverse eventsTreatment Emergent Adverse Events (TEAEs)Time frame: Through study completion, up to Day 183
    Secondary outcomes 8 edited
    What changed in the outcomes
    • EditedPlasma pharmacokinetic (PK) parametersPK ParametersTime frame: Through study completion, up to Day 183 → Day 1
    • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
    • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
    • EditedPlasma pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
    • EditedUrine pharmacokineticPharmacokinetic (PK) parametersParametersTime frame: Through study completion, up to Day 183 → Day 1
    • EditedAOC 1001 levelsConcentration Levels in muscle tissuePlasma, Urine, and Muscle TissueTime frame: Through study completion, up to Day 183 → Up to Day 43
    • EditedChange and percentage change from baselineFrom Baseline in DMPK mRNA knockdownKnockdownTime frame: Through study completion, up to Day 183 → Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
    • EditedAbsolute Change and percentage change from baselineFrom Baseline in 4 Gene SpliceopathyTime frame: Through study completion, up to Day 183 → Day 43 (participants treated with 1 mg/kg) and Day 92 (participants treated with 2 mg/kg and 4 mg/kg)
    + 3 other changes: verification date, registry dates and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05027269
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Oct 28, 2021
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Results posted
Sep 28, 2026
Last update
Sep 28, 2026

Study contacts

Li Tai, MD
study director · Avidity Biosciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AOC 1001

Start the discussion